Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PFSA

Profusa Inc

0.9801

Jul 27 • 12:58 PM ET -0.7299 (-42.68%)

Healthcare Medical Devices USA Nano NASD

Today, 10:40 AMProfusa details stock, preferred equity and $7 million convertible note financing for non-binding term sheet to acquire $111 million‑revenue diagnostics and toxicology firm

Peers: IVF NUWE VTAK AEMD AMIX HSCS INBS XAIR NXL TNON

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	0.52M
Enterprise Value	12.68M
Income	-42.41M
Sales	0.00M
Book/sh	-296.19
Cash/sh	0.71
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jan 24, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	1.37
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.02
Current Ratio	0.02
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-4495.51
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-53.06%
Sales Y/Y TTM	-
EPS Q/Q	87.34%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	0.76%
Insider Trans	0.00%
Inst Own	0.58%
Inst Trans	-
ROA	-2980.89%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-55.53%
SMA50	-81.34%
SMA200	-99.31%
Trades

Shs Outstand	0.53M
Shs Float	0.53M
Short Float	10.04%
Short Ratio	0.30
Short Interest	0.05M
52W High	4162.50 -99.98%
52W Low	1.60 -38.74%
Volatility	16.83% 19.20%
ATR (14)	0.57
RSI (14)	23.88
Beta	5.04
Rel Volume	57.94
Avg Volume	180.15K
Volume	5,810,228

Perf Week	-49.74%
Perf Month	-66.78%
Perf Quarter	-93.21%
Perf Half Y	-99.54%
Perf YTD	-99.50%
Perf Year	-99.92%
Perf 3Y	-100.00%
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.71
Price	0.98
Change	-42.68%

Today 10:38AM	Profusa Signs Term Sheet for Diagnostics Acquisition and Announces Leadership Changes (InvestorsHub) -42.68%
06:00AM	Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company (GlobeNewswire)
Jul-02-26 12:48PM	This Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Year (Stocktwits) -28.08%
11:00AM	Profusa Announces 1-for-25 Reverse Stock Split (GlobeNewswire)
Jun-24-26 08:00AM	Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts (GlobeNewswire) -9.72%
08:00AM	Loading…
Jun-12-26 08:00AM	Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee Oxygen Platform (GlobeNewswire) -17.66%
Jun-10-26 08:00AM	Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting (GlobeNewswire) -9.69%
May-15-26 07:30AM	Profusa Announces Listing Transfer to The Nasdaq Capital Market (GlobeNewswire)
May-08-26 06:00AM	Profusa Receives Favorable Nasdaq Listing Determination (GlobeNewswire) +5.27%
May-05-26 08:30AM	Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value (GlobeNewswire) -6.64%
Apr-28-26 10:30AM	BC-Most Active Stocks (Associated Press) +8.22%
Apr-06-26 10:30AM	BC-Most Active Stocks (Associated Press) +144.06%
06:00AM	Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform (GlobeNewswire)
Feb-27-26 09:15AM	Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering (GlobeNewswire) -14.75%
Feb-19-26 08:30AM	Profusa Receives Purchase Orders for Lumee Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance (GlobeNewswire)
08:30AM	Loading…
Feb-13-26 08:30AM	Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies (GlobeNewswire) -33.44%
Feb-12-26 04:30PM	Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies (GlobeNewswire)
Feb-05-26 08:00AM	Profusa Announces 1-for-75 Reverse Stock Split (GlobeNewswire) -36.35%
Jan-29-26 08:00AM	Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 (GlobeNewswire)
Jan-16-26 12:51PM	Profusa Stock Spikes As Lumee System Targets Research Market (Benzinga)
07:30AM	Profusa Launches Lumee Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue (GlobeNewswire)
Jan-08-26 07:30AM	Profusa Adds Leading Greek Vascular Surgeon to Customer Base (GlobeNewswire)
Dec-31-25 07:30AM	Profusa Bolsters European Commercial Network with New French Distributor, MedSell (GlobeNewswire) -13.96%
Dec-30-25 07:30AM	Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 (GlobeNewswire) +78.33%
Dec-15-25 07:30AM	Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 (GlobeNewswire) -19.87%
Dec-11-25 08:30AM	Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 (GlobeNewswire)
Nov-24-25 08:15AM	Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 (GlobeNewswire) +8.38%
Nov-19-25 05:44PM	Profusa Announces Third Quarter Business and Financial Highlights (GlobeNewswire) -5.95% -19.59%
Oct-30-25 07:30AM	Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee Oxygen and Glucose Monitoring Launches (GlobeNewswire) -9.85%
Oct-28-25 08:30AM	Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026 (GlobeNewswire)
08:30AM	Loading…
Oct-22-25 08:30AM	Profusa Expands Sales Footprint with New Distributor for Lumee Oxygen Platform in Europe (GlobeNewswire) -8.11%
Oct-15-25 08:30AM	Profusa Expands Sales Footprint with New Distributor for Lumee Oxygen Platform in Europe (GlobeNewswire)
Oct-07-25 08:15AM	Profusa Invests Additional $1 Million in Digital Treasury Assets (GlobeNewswire)
Oct-01-25 08:30AM	Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base (GlobeNewswire)
Sep-11-25 08:45AM	Report Highlights Growth in AI Biomarker Monitoring as Industry Giant's GPUs Power Next-Gen Platform (PR Newswire) +74.04%
08:30AM	Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring (GlobeNewswire)
Sep-04-25 08:30AM	Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base (GlobeNewswire) -7.94%
Sep-02-25 04:05PM	Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) -7.83% -5.00%
Aug-27-25 08:45AM	Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria (GlobeNewswire)
Aug-19-25 08:15AM	Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO (GlobeNewswire) -7.99%
Aug-06-25 08:15AM	Profusa, Inc. Provides Strategy Overview and Business Update for Investors (GlobeNewswire) -7.72%
Jul-31-25 08:15AM	Profusa Secures Lumee Oxygen Platform Distributor in Spain (GlobeNewswire)
Jul-30-25 08:00AM	Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy (GlobeNewswire) -17.80%
Jul-21-25 08:00AM	Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy (GlobeNewswire) -17.32%
Jul-11-25 04:00PM	Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq (GlobeNewswire) -80.02% -19.20%

Profusa, Inc. engages in biofeedback for chronic disease management and healthy living services. The company is founded by Natalie Wisniewski and Bill McMillan and is headquartered in Berkeley, CA.

CEO & ChairmanDr. Ben Chung-Bin Hwang Ph.D.

Chief Financial OfficerMr. Fred S. Knechtel

Co-founderMr. William McMillan

Head of Digital Health BusinessMr. David Icke

Head of Government BusinessMr. Sean Givens

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PFSA

Profusa Inc

Upgrade your Finviz experience